ProfileGDS5678 / 1435133_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 85% 87% 85% 87% 86% 84% 85% 83% 88% 86% 89% 87% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5238986
GSM967853U87-EV human glioblastoma xenograft - Control 26.4724985
GSM967854U87-EV human glioblastoma xenograft - Control 36.6617587
GSM967855U87-EV human glioblastoma xenograft - Control 46.5012585
GSM967856U87-EV human glioblastoma xenograft - Control 56.6967587
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3491786
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0831284
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3912685
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0976783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8243488
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4641486
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0389689
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7435287
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8059788